Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-0617-2020

Drug recall · December 18, 2019

Ranitidine Tablets recall

Why: CGMP Deviations: Presence of NDMA impurity detected in product.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Ranitidine Tablets, USP 150 mg, OTC, a.) 30 count bottle (NDC 68788-7078-03), b.) 60 count bottle (NDC 68788-7078-06), Mfg: Amneal Pharmaceuticals

Lots / codes

Lot #: I2519H, Exp. 12/20; I2719O, Exp. 12/20; J1419O, Exp. 12/20; J2819L, Exp. 12/20

Quantity
316 bottles
Company
Preferred Pharmaceuticals, Inc, Anaheim, CA
Distribution
CA, FL
Initiated
December 2, 2019 · Voluntary: Firm initiated
Classified
December 9, 2019
Reported
December 18, 2019
Ended
May 9, 2023
How notified
E-Mail

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Ranitidine

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.